About Us

We are advancing potential
therapies to improve the
futures of people living
with devastating
neuromuscular and
neurological diseases

A clinical stage biotech company, PepGen is advancing a new generation of oligonucleotide therapies capable, for the first time, of potentially transforming clinical outcomes for individuals with neuromuscular and neurological diseases.

We are leveraging our Enhanced Delivery Oligonucleotide (EDO) platform to solve the delivery challenges associated with previous generations of therapies and, achieve deep tissue penetration and high uptake to key muscle tissues.

We have a bold goal, and we won’t stop until we reach it

We are committed to developing truly transformative therapies resulting in clinically meaningful outcomes for individuals living with neuromuscular and neurological diseases including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), and ultimately, will expand into additional indications.

Team

Together we can solve the most difficult challenges and create a new future

We are scientists, physicians, advocates and biotech industry leaders. We bring expertise across scientific, medical, and business disciplines.

But our superpower is our commitment to changing the future.

Executive Team

JAMES MCARTHUR, PHD

President and Chief Executive Officer

MARY BETH DELENA, JD

General Counsel and Secretary

NOEL DONNELLY, MBA

Chief Financial Officer

PAUL STRECK, MD, MBA

Executive Vice President, Head of Research & Development

MICHELLE MELLION, MD

Chief Medical Officer

DAVE BORAH, MBA, CFA

Senior Vice President, Investor Relations and Corporate Communications

AFSANEH MOHEBBI, PHD

Senior Vice President, Portfolio and Program Management

HAYLEY PARKER, PHD

Senior Vice President, Global Regulatory Affairs

NIELS SVENSTRUP, PHD

Senior Vice President, Biological Chemistry

Senior Leadership

KYLE BREIDENSTINE, MBA, CPA

Vice President, Finance & Controller

EMIKO BRYANT

Chief of Staff

JEFFREY FOY, PHD

Vice President, Toxicology

PATRICIA FRASER, MD

Vice President, Pharmacovigilance

JANE LARKINDALE, DPHIL

Vice President, Clinical Science

PALLAVI LONKAR, PHD

Vice President, Bioanalytical, Biomarkers, and DMPK

DEBRA SAWYER

Vice President, Quality Assurance

Board Of Directors

JAMES MCARTHUR, PHD

President and Chief Executive Officer
LEARN MORE
LAURIE KEATING, JD

Board Chair
LEARN MORE
JOSH RESNICK, MD, MBA

Non-Executive Director
LEARN MORE
HEIDI HENSON

Non-Executive Director
LEARN MORE
HABIB JOSEPH DABLE

Non-Executive Director
LEARN MORE
HOWARD MAYER, MD

Non-Executive Director
LEARN MORE

Scientific Advisors

MATTHEW WOOD, PHD, MD

Professor of Neuroscience, Oxford University
LEARN MORE
BRENDA WONG, MD

Founding Director, UMass Duchenne Program
LEARN MORE
JONATHAN WATTS, PHD

Professor, UMass Medical School
LEARN MORE
CHARLES THORNTON, MD

Professor of Neurology & Neuroscience, U Rochester Medical Center
LEARN MORE
BETH MCNALLY, MD

Director, Center for Genetic Medicine, Northwestern University
LEARN MORE
ART KRIEG, MD

Former President of the Oligonucleotide Therapeutics Society
LEARN MORE
MICHAEL GAIT, PHD

Founder
LEARN MORE
JOHN W. DAY, MD, PHD

Professor of Neurology, Pediatrics (Genetics) and Pathology, Stanford University
LEARN MORE